PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15084480-8	2004	OA-induced MAPK activation was inhibited by butyrolactone I, an inhibitor of cyclin-dependent kinases 1 and 2 (CDK1, CDK2); thus, these kinases may regulate MAPK activity.	4-Butyrolactone	44-57	cyclin-dependent kinase 2	Mus musculus	117-121	
10692433-10	2000	Experiments utilizing a chemical Cdk-specific inhibitor, butyrolactone I, revealed that Cdk2 activity was required only for chromatin binding of the Cdc45 proteins, and not for the expression of Cdc45 or chromatin binding of MCM4 and -7.	4-Butyrolactone	57-70	cyclin-dependent kinase 2	Mus musculus	88-92	
8395680-3	1993	Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase.	4-Butyrolactone	0-13	cyclin-dependent kinase 2	Mus musculus	35-39	
8395680-7	1993	Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.	4-Butyrolactone	5-18	cyclin-dependent kinase 2	Mus musculus	84-88